Grant name: NCCIH Natural Product Early Phase Clinical Trial Award (R33)
Funding organization: National Institutes of Health (NIH)
Total funding amount: Up to $1,050,000 in direct costs
Duration: Up to 3 years
Primary objective: Support early phase clinical trials of natural products with a strong scientific premise.
Key stakeholders: Researchers, healthcare providers, patients.
Funding source: Federal government (NIH).
Funding type: Grant.
Significance: Addresses the need for rigorous investigation of natural products in clinical settings.
Grant frequency: One-time funding opportunity.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local, State, County, City Governments
Indian/Native American Tribal Governments (Federally Recognized and Other)
Federal Government Agencies
Independent School Districts
Public Housing Authorities
Faith-based or Community-based Organizations
Regional Organizations
Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic components of U.S. Organizations are not eligible to apply.
Natural products including botanicals, dietary supplements, and probiotics.
Studies must demonstrate a strong scientific premise for further clinical testing.
Efficacy or effectiveness trials.
Trials testing natural products for the treatment or prevention of cancer.
Investigators must have experience in leading clinical trials.
A multidisciplinary team is encouraged.
Maximum grant amount: $1,050,000 in direct costs.
No cost-sharing is required.
Open Date: May 23, 2025
Application Due Dates: Various dates until October 20, 2026
Expiration Date: November 14, 2026
Must adhere to FDA regulations for clinical research.
Investigators must contact the FDA to determine if an IND application is necessary.
Applications must follow the instructions in the Research Instructions in the How to Apply - Application Guide.
A letter of intent is encouraged but not required.
Applications must be hypothesis-driven and milestone-oriented.
Studies should include a placebo arm.